Business
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Announced positive interim data from the Phase 2b ORIGIN clinical trial of atacicept in IgAN, which showed a 41% mean reduction in proteinuria versus baseline
About this update from Vera Therapeutics, Inc.
[{"type":"text","content":"Announced positive interim data from the Phase 2b ORIGIN clinical trial of atacicept in IgAN, which showed a 41% mean reduction in proteinuria versus baseline in the 150mg dose group at 24 weeks36-week data from the Phase 2b ORIGIN clinical trial of atacicept in IgAN on track for the second quarter of 2023Management prioritizing advancement of atacicept in IgAN, plans to initiate Phase 3 clinical trial in second quarter of 2023 Strong balance sheet expected to fund IgAN-focused operations to early 2026 BRISBANE, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights for the fourth quarter and financial results for the full year ended December 31, 2022. “Over the past year, we have made significant progress executing our clinical development program for our lead product candidate, atacicept, for the treatment of IgA Nephropathy (IgAN),” said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. “We believe the recently announced positive efficacy and safety data from the ORIGIN study have further de-risked the atacicept program and position it as a potential best-in-disease therapy. We expect to announce 36-week results from the ORIGIN study in the second quarter of this year and initiate a pivotal Phase 3 trial for atacicept in IgAN during the second quarter of this year.” “Given the significant market opportunity and unmet need of IgAN patients, we made the strategic decision to prioritize and focus both our financial and organizational resources at this time on the advancement of atacicept into a Phase 3 pivotal trial for IgAN,” continued Dr. Fordyce. Full Year 2022 and Recent Business Highlights Released positive interim data from the Phase 2b ORIGIN clinical trial of atacicept in IgAN, which showed a 41% mean reduction in proteinuria versus baseline in the 150mg dose group at 24 weeksAnnounced data in oral presentation at the 59th European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress showing the effect of atacicept on serum anti-Gd-IgA1 in IgAN patientsPresented final results from the Phase 2a clinical trial of MAU868 in patients with reactivated BK Vir...